NORGES BANK - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.

Quarter-by-quarter ownership
NORGES BANK ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$53,956,620
+38.0%
948,271
-4.1%
0.01%
+30.0%
Q3 2022$39,104,625
-28.0%
988,989
-19.8%
0.01%
-28.6%
Q2 2022$54,284,164
+14.8%
1,233,731
+4.1%
0.01%
+40.0%
Q1 2022$47,284,320
+12.4%
1,185,665
+13.3%
0.01%
+11.1%
Q4 2021$42,068,000
+0.9%
1,046,198
+2.1%
0.01%0.0%
Q3 2021$41,684,000
+13.7%
1,024,681
+26.9%
0.01%
+12.5%
Q2 2021$36,670,000
-26.7%
807,540
-32.7%
0.01%
-27.3%
Q1 2021$50,005,000
+3.0%
1,199,438
+5.5%
0.01%0.0%
Q4 2020$48,546,000
+76.4%
1,136,645
+8.5%
0.01%
+57.1%
Q3 2020$27,519,000
-15.1%
1,047,150
-13.3%
0.01%
-22.2%
Q2 2020$32,399,000
+17.8%
1,208,474
-20.9%
0.01%
-10.0%
Q1 2020$27,498,000
-9.2%
1,528,524
-10.5%
0.01%
+25.0%
Q4 2019$30,288,000
+7.9%
1,708,271
-5.6%
0.01%
-11.1%
Q3 2019$28,076,000
-0.1%
1,810,203
+10.7%
0.01%0.0%
Q2 2019$28,093,000
+7.8%
1,635,203
+1.0%
0.01%
+12.5%
Q1 2019$26,062,000
+10.0%
1,618,7600.0%0.01%
-11.1%
Q4 2018$23,682,000
-19.5%
1,618,7600.0%0.01%
-10.0%
Q3 2018$29,412,000
+7.7%
1,618,7600.0%0.01%
+11.1%
Q2 2018$27,309,000
+33.3%
1,618,760
+54.8%
0.01%
+28.6%
Q1 2018$20,484,000
+1.6%
1,045,610
+5.1%
0.01%0.0%
Q4 2017$20,159,000
+16.6%
995,0080.0%0.01%0.0%
Q3 2017$17,283,000
+35.5%
995,0080.0%0.01%
+40.0%
Q2 2017$12,756,000
-3.0%
995,008
-2.0%
0.01%0.0%
Q1 2017$13,153,000
+31.2%
1,014,8520.0%0.01%
+25.0%
Q4 2016$10,026,000
-14.4%
1,014,8520.0%0.00%
-33.3%
Q3 2016$11,709,000
+62.0%
1,014,852
+21.2%
0.01%
+100.0%
Q2 2016$7,229,000
-25.1%
837,637
-17.8%
0.00%
-40.0%
Q1 2016$9,654,000
-49.6%
1,019,337
-7.8%
0.01%
-50.0%
Q4 2015$19,156,000
+29.0%
1,105,3370.0%0.01%
+25.0%
Q3 2015$14,845,000
-17.3%
1,105,337
+39.1%
0.01%
-11.1%
Q2 2015$17,945,000
+69.8%
794,752
+7.4%
0.01%
+80.0%
Q1 2015$10,569,000
+48.0%
740,1520.0%0.01%
+25.0%
Q4 2014$7,142,000
-23.9%
740,152
-28.2%
0.00%
-20.0%
Q3 2014$9,382,000
-53.9%
1,031,007
-50.0%
0.01%0.0%
Q2 2014$20,370,000
+55.6%
2,062,014
+100.0%
0.01%
-28.6%
Q1 2014$13,094,000
-15.3%
1,031,0070.0%0.01%
-22.2%
Q4 2013$15,454,000
+27.1%
1,031,007
-6.4%
0.01%
+28.6%
Q3 2013$12,156,000
+39.0%
1,101,0430.0%0.01%
+40.0%
Q2 2013$8,743,000
+144.5%
1,101,043
+77.7%
0.01%
+150.0%
Q1 2013$3,576,000
-1.1%
619,773
+29.5%
0.00%0.0%
Q3 2012$3,617,000
-16.2%
478,5300.0%0.00%
-33.3%
Q2 2012$4,316,000478,5300.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders